Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT ID: NCT00280241

Last Updated: 2016-02-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-06-30
• Study Completion Date: 2013-01-31

Brief Summary

This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and this study will evaluate the side effects and effectiveness of this combination.

Detailed Description

This study is designed to expand on the highly successful combination of rituximab, fludarabine and cyclophosphamide for patients with previously untreated CLL. Responses in the range of 90-98% with 55% complete responses are reported. However, bone marrow toxicity has been a significant problem. This trial is designed to reduce the bone marrow toxicity by decreasing the doses of fludarabine and cyclophosphamide, but doubling the dose of rituximab with a maintenance dose of rituximab for up to two years, to maintain or even enhance efficacy.

Conditions

Chronic Lymphocytic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FLUDARABINE, CYCLOSPHOSPHAMIDE AND RITUXIMAB

Group Type: EXPERIMENTAL

Fludarabine

Intervention Type: DRUG

Fludarabine is usually administered by IV infusion over 30 minutes or longer.

Cyclophosphamide

Intervention Type: DRUG

The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.

Rituximab

Intervention Type: DRUG

First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.

Interventions

Fludarabine

Fludarabine is usually administered by IV infusion over 30 minutes or longer.

Intervention Type: DRUG

Cyclophosphamide

The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.

Intervention Type: DRUG

Rituximab

First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of CD20 + CLL
• Peripheral blood absolute lymphocyte count of > 5,000/mm3 obtained within 2 weeks prior to randomization.
• The lymphocytosis must consist of small to moderate size lymphocytes, with ≤55% (no greater than 55%) prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically.
• Phenotypically characterized CD20 + CLL defined as: 1) the predominant population of cells share B-cell antigens with CD5 in the absence of other pan-T-celI markers (CD3, CD2, etc.); 2) B-cell expresses either kappa or lambda light chains; and 3) surface immunoglobulin (slg) with low-cell surface density expression.
• Splenomegaly, hepatomegaly or lymphadenopathy are not required for the diagnosis of CLL.
• Must require chemotherapy. Indications for chemotherapy are one or more of the following:
• One or more of the following disease-related symptoms
• Weight loss >10% within the previous 6 months.
• Fevers of greater than 100.0° F for 2 weeks without evidence of infection.
• Night sweats without evidence of infection.
• Evidence of progressive marrow failure as manifested by the development of or worsening of anemia (< 10 g/dl) and/or thrombocytopenia (< 100,000/mm3).
• Massive (i.e., > 6 cm below left costal margin) or progressive splenomegaly.
• Massive nodes or clusters (i.e., > 10 cm in longest diameter) or progressive
• adenopathy.
• Progressive lymphocytosis with an increase of> 50% over 2 month period, or an anticipated doubling time of less than 6 months.
• NOTE: Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease are not sufficient for protocol therapy.
• Serum creatinine <1.5 mg/dl.
• Bilirubin must be <2 mg/dl, unless secondary to tumor, obtained within 2 weeks prior to randomization.
• Age >18 years.
• Not pregnant (confirmed by serum pregnancy test in females of reproductive potential) or breast feeding, because it is unknown what effect these drugs will have on children.
• ECOG performance status 0-2.
• AST or ATL >2x upper limit of normal unless related to CLL.
• Subject has provided written informed consent.

Exclusion Criteria

• Subjects with autoimmune anemia or thrombocytopenia are not eligible.
• No prior cytotoxic chemotherapy. Patients with a history of steroid treatment for CLL, autoimmune hemolytic anemia, or autoimmune thrombocytopenia are not eligible.
• Subjects with active infections requiring oral or intravenous antibiotics until resolution of the infection and completion of therapeutic antibiotics.
• Women of childbearing potential and sexually active males who refuse to use an accepted and effective method of contraception.
• Subjects with a second malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix are not eligible unless the tumor was treated with curative intent at least two years previously.
• History of HIV
• CNS disease
• History of psychiatric disorder that would make it difficult to enroll and follow the patient on trial.
• New York Heart Classification III or IV heart disease.
• Hepatitis BsAg or Hepatitis C positive.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

Biogen

INDUSTRY

Sponsor Role: collaborator

University of Pittsburgh

OTHER

Sponsor Role: lead

Responsible Party

Michael Boyiadzis

Study Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Micahel Boyiadzis, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh Medical Center

Locations

Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Countries

United States

Other Identifiers

03-136

Identifier Type: -

Identifier Source: org_study_id